DDDavid J. Dabbs

David J. Dabbs

*This is an algorithmically generated author record based on publicly available information.

David J. Dabbs has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • High Fidelity of Breast Biomarker Metrics: A 10-Year Experience in a Single, Large Academic Institution

    by Huina Zhang, Min Han, Kavita R. Varma, Beth Z. Clark, Rohit Bhargava, David J. Dabbs

    Purpose: Recommendations for standardization of breast biomarkers including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) led to the creation of American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines to provide continuous guidance. Included in these recommendations is the “ongoing assay assessment procedures.” We report these biomarker metrics as there is a dearth of published information on this topic. Materials and Methods: ER, PR, and HER2 positivity rates of all newly diagnosed, recurrent, and metastatic invasive breast cancers on core biopsies, and repeated testing on resection specimen by immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH) were collected from April 1, 2008 to December 31, 2017. Results: The positivity rates of ER, PR, and HER2 over almost 10 years of monitoring showed high fidelity. Total ER-positive rate was 83.6% (81.4% to 86.8%), ER+/PR+ was 71.7% (68.6% to 75.5%), ER+/PR− was 17.6% (11.0% to 15.0%), ER−/PR− was 16.0% (13.5% to 18.2%), and ER−/PR+ was 0.6% (0.2% to 1.0%). The HER2-positive rate was 13.7% (10.2% to 17.4%) including 9.9% (7.3% to 11.9%) by IHC and 3.8% (1.9% to 5.9%) by FISH reflexed from IHC 2+ results. FISH amplification rate of HER2 IHC 2+ cases was 11.0% (5.8% to 19.2%). Annual quality-assurance check for HER2 IHC/FISH percent positive and percent negative agreement (as defined by Food and Drug Administration) was 96% to 100%. Conclusions: This longitudinal active assessment of 9564 breast biomarker cases shows the achievement of high fidelity of breast biomarker results when following the ASCO/CAP guidelines. Continuous monitoring of breast biomarkers may minimize assay analytical drift and assure quality clinically relevant results.


  • Mitotic index to predict breast cancer recurrence after neoadjuvant systemic therapy.

    by Daniel J. Farrugia, Alessandra Landmann, Emilia Diego, Priscilla F. McAuliffe, Ronald Johnson, Marguerite Bonaventura, Atilla Soran, David J. Dabbs, Beth Clark, Shannon Puhalla, et al.

    E23265 Background: For breast cancer patients that do not achieve pathologic complete response (pCR) after neoadjuvant therapy (NAT), a straightforward prognostic indicator is lacking. The mitotic index is routinely measured on breast specimens after completion of NAT along with tubular formation score (TS) and nuclear pleomorphism score (NS) as part of the Nottingham Grade (NG) and is inexpensive and reproducible. We hypothesized that Mitotic Count Score (MCS), that ranges from 1-3, is a predictor of tumor recurrence in patients that do not achieve pCR. Methods: We retrospectively identified consecutive breast cancer patients who received NAT at our institution from 2010-2014. Of 614 patients, we eliminated 160 patients that achieved pCR (no tumor in breast or axilla) and 89 that did not have NG available. 367 remained eligible for inclusion. Of these, 251 were hormone receptor (HR) +ve and 116 were HR -ve. 83 were triple negative tumors (TNBC, 22.6%). 98 were HER2 +ve (26.7%) independent of HR status. Mean follow up was 32.8 months. Chi-Square analysis was performed. Results: Breast cancer recurrence showed a statistically significant proportional relationship with MCS (see table below). MCS remained associated with tumor recurrence on subset analysis for both HR+ (p < 0.0001) and HR- (p = 0.037) tumors independent of HER2 status, and on subset analysis for TNBC (p = 0.043). It also remained associated in premenopausal patients (p < 0.0001), and in the presence of lymph node (LN) metastases at time of surgery (p < 0.0001). NG and its remaining components TS and NS showed a much weaker association with tumor recurrence, and lost statistical significance on subset analysis for HR- and TNBC. The association of either MCS or NHG with recurrence did not reach statistical significance on subset analysis for HER2+ve tumors. Conclusions: In patients who do not achieve pCR after NAT, MCS is a simple inexpensive assay that predicts breast cancer recurrence and is independent of HR, menopausal status or LN positivity. A larger sample is needed to validate these results in HER2+ tumors.


  • Utilization of Magee equation 3 in ER-positive, HER2-negative/equivocal tumors to determine pathologic response to neoadjuvant therapy.

    by Daniel J. Farrugia, Alessandra Landmann, Emilia Diego, Priscilla F. McAuliffe, Ronald Johnson, Marguerite Bonaventura, Atilla Soran, David J. Dabbs, Shannon Puhalla, Rachel Catherine Jankowitz, et al.

    11594 Background: Magee Equations (ME) were derived to estimate Oncotype DX scores (Mod Pathol. 2013;26:658-64). ME3 uses only the immunohistochemical/FISH data for ER, PR, HER2 and Ki-67 for calculation (24.30812+ERIHC*(−0.02177)+PRIHC*(−0.02884)+(0 for HER2-ve, 1.46495 for equivocal, 12.75525 for HER2+ve)+Ki-67*0.18649). We hypothesized that ME3 scores from pre-therapy core biopsy can be used to predict response to NAT. Methods: A retrospective chart review was conducted of patients who received NAT from 2010-2014 at a single institution. Of 595 patients that had tumor ER status, HER2 status and pathologic complete response (pCR) information available, we excluded 359 tumors that were ER -ve or showed unequivocal HER2 gene amplification. pCR was defined as absence of invasive tumor in the breast and regional lymph nodes (LN). ME3 scores were grouped into 3 categories similar to Oncotype DX, i.e. 0 to <18, 18 to <31, and ≥31. Univariate analyses were performed using Fisher exact test. Results: 236 ER+, HER2 -ve/equivocal tumors were eligible for consideration. Mean followup was 33.3 months. Table 1 shows that pCR rate increases with higher ME3 score categories (RR 27 for ME3 ≥31 vs <18). For patients that do not achieve pCR, ME3 score ≥31 correlates with increased risk of overall recurrence, with the majority occurring in patients with +ve LN in the resection specimen (Table 2). Conclusions: ME3 score ≥31 predicts for pCR in the neoadjuvant setting and paradoxically for tumor recurrence when pCR is not achieved. These results validate the use of ME3 in selecting patients who will benefit from chemotherapy but require validation outside a single institution.

  • HER2 equivocal breast cancer and neoadjuvant therapy: Is response similar to HER2-positive or HER2-negative tumors?

    by Alessandra Landmann, Daniel J. Farrugia, Emilia Diego, Marguerite Bonaventura, Atilla Soran, Ronald Johnson, David J. Dabbs, Beth Clark, Adam Brufsky, Nancy E. Davidson, et al.

    612 Background: While HER2+breast cancers demonstrate high rates of pathologic complete response (pCR) to neoadjuvant HER2-targeted therapy, there is a need to assess objective response in HER2 equivocal tumors. Methods: Retrospective chart review was conducted of patients diagnosed with invasive breast cancer who received neoadjuvant therapy (NAT) between 2010 and 2014 at our institution. Case inclusion required at least ER and HER2 status and pCR information. HER2 was measured by immunohistochemistry (IHC) with IHC 3+ and IHC 0/1+ cases considered positive and negative respectively. IHC 2+ cases were tested by FISH and classified using the 2013 ASCO HER2 guidelines ISH criteria for dual color probe. Cases were also classified by average HER2 copies/cell criteria. Results: 595 cases met criteria for inclusion. pCR rates according to HER2 status are reported below. Conclusions: Of the 46 patients with HER2 equivocal results, 31 (67%) received anti-HER2 NAT. 5 of 31 (16%) achieved pCR: 2 of 8 ER- (25%) and 3 of 23 ER+ (13%). The overall 16% pCR rate of HER2 equivocal tumors that received targeted therapy is similar to the 18% pCR rate of HER2- tumors (p = 1.0), but significantly lower than the 41% pCR rate of HER2+ tumors (p = 0.0087). In this small subset of HER2 equivocal cases treated with anti-HER2 NAT, pCR rates were similar to HER2- tumors. Further study is warranted to assess whether HER2 targeted therapy in HER2 equivocal tumors improves surgical outcomes, and survival.


  • Low estrogen receptor (ER) positive breast cancer and neoadjuvant systemic therapy (NAT): Is response similar to ER+ or to ER- disease?

    by Alessandra Landmann, Daniel J. Farrugia, Emilia Diego, Atilla Soran, Ronald Johnson, Marguerite Bonaventura, David J. Dabbs, Beth Clark, Adam Brufsky, Nancy E. Davidson, et al.

    580 Background: ER expression can be semi-quantitatively measured using a Histochemical or H-score that can range from 0 (negative) to 300 (diffuse strong positive).. We sought to demonstrate a difference in pathologic complete response (pCR) rates after NAT between strongly positive and weakly positive ER+ breast cancers. Methods: Retrospective chart review was conducted of patients diagnosed with invasive breast cancer who received NAT from 2010-2014 at our institution. Case inclusion required at least tumor ER status, HER2 status and pCR information. Low ER+ tumors were defined as tumors with ER H-score of 1-100 and their overall pCR rate was compared to that of ER negative (H-score 0), moderate ER+ (H-score 101-200) and high ER+ tumors (H-score 201-300). The data was further analyzed with respect to HER2 status. HER2 results were classified using the 2013 ASCO/CAP HER2 guidelines criteria. HER2 equivocal cases were excluded for this analysis due to small numbers. Univariate analyses were performed using Fisher exact test. All reported p-values are 2 tailed. Results: Of 595 cases, ER H-score information was available on 580 cases. The pCR rate of ER-, low ER+, moderate ER+, high ER+ tumors was 35.6% (78 of 219), 36.3% (29 of 80), 20% (18 of 90), and 9.4% (18 of 191) respectively, and decreased with increasing ER H-score. The pCR rate of low ER+ tumors was similar to that of ER- tumors (p = 1.0) and significantly different from moderate (p = 0.0251) and high ER+ tumors (p < 0.0001). On subset analysis for HER2 status, pCR rate again increased with lower ER H-score in a statistically significant manner in HER2- tumors but not in the HER2+ subset, presumably due to small numbers and the efficacy of modern anti-HER2 therapy that renders ER status less relevant. Conclusions: The pCR rate of low ER+ tumors is similar to ER- tumors. In HER2- tumors, ER H-score is an important determinant of response to NAT.

  • Top Cited Papers
    Open Access

    Breast cancer prognostic classification in the molecular era: the role of histological grade

    by Emad A Rakha, Jorge S Reis-Filho, Frederick Baehner, David J Dabbs, Thomas Decker, Vincenzo Eusebi, Stephen B Fox, Shu Ichihara, Jocelyne Jacquemier, Sunil R Lakhani, et al.

    Breast cancer is a heterogeneous disease with varied morphological appearances, molecular features, behavior, and response to therapy. Current routine clinical management of breast cancer relies on the availability of robust clinical and pathological prognostic and predictive factors to support clinical and patient decision making in which potentially suitable treatment options are increasingly available. One of the best-established prognostic factors in breast cancer is histological grade, which represents the morphological assessment of tumor biological characteristics and has been shown to be able to generate important information related to the clinical behavior of breast cancers. Genome-wide microarray-based expression profiling studies have unraveled several characteristics of breast cancer biology and have provided further evidence that the biological features captured by histological grade are important in determining tumor behavior. Also, expression profiling studies have generated clinically useful data that have significantly improved our understanding of the biology of breast cancer, and these studies are undergoing evaluation as improved prognostic and predictive tools in clinical practice. Clinical acceptance of these molecular assays will require them to be more than expensive surrogates of established traditional factors such as histological grade. It is essential that they provide additional prognostic or predictive information above and beyond that offered by current parameters. Here, we present an analysis of the validity of histological grade as a prognostic factor and a consensus view on the significance of histological grade and its role in breast cancer classification and staging systems in this era of emerging clinical use of molecular classifiers.


  • Open Access

    Invasive lobular carcinoma with extracellular mucin production and HER-2 overexpression: a case report and further case studies

    by Jing Yu, Rohit Bhargava, David J Dabbs

    Invasive lobular carcinomas (ILC) of breast typically demonstrate intracytoplasmic mucin. We present a unique case of classical type ILC with abundant extracellular mucin and strong ERBB2 (HER2/neu) expression confirmed by immunohistochemistry and fluorescent in situ hybridization. Dual E-cadherin/p120 immunohistochemical stain demonstrated complete loss of membranous E-cadherin and the presence of diffuse cytoplasmic p120 staining, confirming the lobular phenotype. The tumor cells showed ductal-like cytoplasmic MUC1 staining, but were negative for MUC2 and other mucin gene markers. In addition, studies of tissue microarrays of 80 breast carcinomas with mucinous differentiation revealed 4 pure mucinous carcinomas showing significantly reduced E-cadherin staining without redistribution of p120 into cytoplasm. The findings suggest that the presence of extracellular mucin does not exclude a diagnosis of lobular carcinoma, and the morphologic and molecular characteristics of lobular and ductal carcinomas are more complex than previously appreciated.


  • Open Access

    Luminal B breast tumors are not HER2 positive

    by Rohit Bhargava, David J Dabbs


  • Open Access

    Introduction of the Thin Prep Imaging System™ (TIS): experience in a high volume academic practice

    by Mamatha Chivukula, Reda S Saad, Esther Elishaev, Susan White, Nancy Mauser, David J Dabbs

    Objective: Since the introduction of the liquid-based ThinPrep testing in 1996, most cytology laboratories across the country have adopted the liquid-based cytology (LBC) for Pap test screening. Subsequent to wide-spread adoption of the ThinPrep Pap test, the ThinPrep Imaging System (TIS) Cytyc Corp, Marlborough, MA was introduced to improve the accuracy and efficiency of screening interpretation. We report our initial experience with the TIS at Magee Women's Hospital. We introduced the TIS in December 2004. Methods: The imager assisted Pap test results over the first 12 months (December 2004 to December 2005) of implementation were reviewed and analyzed. Our implementation protocol included each cytotechnologist manually prescreening 200 negative slides to gain experience with the imager slides and serve as a quality check for the TIS. We re-screened 3400 slides (200 slides each for 17 cytotechnologists) manually which were initially determined to be negative using the TIS. 104,457 Pap tests were imaged on the TIS. 95,899 manually screened Pap tests, 12 months prior to the introduction of the TIS (December 2003–November 2004) are taken as the historic control group for our study. Results: The mean ASC-US rate employing the automated imager was 8.70% [9088/104,457]. The mean LSIL detection rate was 4.22% [4409/104,457]. The imager did not miss any detectible high-grade lesions during these months, with a HSIL (+) detection rate of 0.68% in comparison to 0.60% by manual screening confirmed by follow-up biopsies. The difference is statistically significant with a p value of 0.022. The definition of false negative rate for purposes of this study is calculated as the number of false negative cases identified out of number of negatives re-screened. The TIS false negative rate was estimated at 0.012% [4/3400]. Conclusion: The overall performance of the TIS in our lab appears to be highly satisfactory in terms of improving sensitivity in screening cervical precursor lesions. The increased accuracy of detection of HSIL indicates a positive impact of the TIS in our laboratory.


  • Molecular alterations in columnar cell lesions of the breast

    by David J Dabbs, Gloria Carter, Mary Fudge, Yan Peng, Pat Swalsky, Sidney Finkelstein